Capricor reports Q3 net loss $24.6M; HOPE-3 topline DMD data expected in Q4 2025

CAPRICOR THERAPEUTICS, INC.

2025-Q3 EPS reported -$1.64 vs consensus -$0.56 ▼ miss (-193.6%)

Net loss of $24.6M ($0.54/share) vs $12.6M ($0.38) in Q3 2024; operating expenses $26.3M, up 72%.
Revenue $0 vs $2.3M in prior year; prior revenue from Nippon Shinyaku milestones now fully recognized.
Cash $98.6M as of Sept 30, down from $151.5M at Dec 31, 2024; runway into Q4 2026.
Topline results from HOPE-3 Phase 3 trial of Deramiocel for Duchenne cardiomyopathy expected in Q4 2025.
FDA supported submitting HOPE-3 results for BLA resubmission (Type A meeting); PLI completed with all 483 observations addressed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.